Aman B. Upaganlawar

Dr. Aman B. Upaganlawar


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2024 in Ageing Research Reviews
Verified
Journal Article
Closed access
MKMayur Bhimrao Kale
Mayur Bhimrao Kale
NWNitu Wankhede
Nitu Wankhede
RPRupali Pawar
Rupali Pawar
SBSuhas Ballal
Suhas Ballal
RKRohit Kumawat
Rohit Kumawat
Sushruta KoppulaSushruta Koppula
Sushruta Koppula

4 April 2023 in Biophysical Reviews
Verified
Journal Article
Closed access
PDF file
TBTrupti A. Banarase
Trupti A. Banarase
SSShivkumar S. Sammeta
Shivkumar S. Sammeta
NWNitu L. Wankhede
Nitu L. Wankhede
SMSHUBHADA V MANGRULKAR
SHUBHADA V MANGRULKAR
SRSandip R. Rahangdale
Sandip R. Rahangdale
MKMayur Bhimrao Kale
Mayur Bhimrao Kale

1 September 2022 in Current Drug Metabolism
Verified
Journal Article
Closed access
PDF file
AUAman B. Upaganlawar
Aman B. Upaganlawar
SPSatish Polshettiwar
Satish Polshettiwar
SRSushil Raut
Sushil Raut
ATAmol Tagalpallewar
Amol Tagalpallewar
VPVishal Pande
Vishal Pande
Background: Global cancer statistics defines the severity of disease even after significant research worldwide. Problem: Failure of the currently available treatment approaches, including surgery, radiation therapy and traditional chemotherapy. Aim: The aim of this review is to discuss the role of phytochemical based nano-formulations for treatment of cancer. Discussion: In the past few decades, phytochemicals have gained popularity for acting as a potential anticancer treatment with low systemic toxicity, especially in terms of cell cycle control and cancer cell killing. Natural resources, with their immense structural variety, serve as a vital source of fresh, therapeutically useful new chemical entities for the treatment of cancer. Vinca alkaloids (VCR), vinblastine, vindesine, vinorelbine, taxanes (PTX), podophyllotoxin and its derivatives (etoposide (ETP), teniposide, camptothecin (CPT) and its derivatives (topotecan, irinotecan), anthracyclines (doxorubicin, daunorubicin, epirubicin, idarubicin, as natural products or their derivatives account for half of all anticancer drugs approved worldwide, and they have been developed utilising the knowledge learned from the natural small molecules or macromolecules. Trabectedin, an epothilone derivative, ixabepilone, and temsirolimus, three new anticancer medications launched in 2007, were derived from microbial origins. Current therapy regimens require selective drug targeting to enhance efficacy against cancer cells while normal cells remain unharmed. Modified medications and systems for drug delivery based on nanotechnology are in the process of being explored and launched in the industry for enhanced therapy and management of cancer, along with promising outcomes. Many obstacles related to cancer cell drug delivery can be overcome by using nano-particulate drug carriers, including enhancing the stability and solubility of the drug, prolonging half-lives of the drug in the blood, decreasing side effects to undesired organs, and increasing medication concentration at the desired site. The scientific initiatives and studies concerning the use of nanotechnology for some selective compounds derived from plants are discussed in this review article. Conclusion: The present review highlights the phytochemical-based nanoformulations and their strategies in the development of novel systems of drug delivery such as nano-liposomes, functionalized nanoparticles (NPs), and polymer nano-conjugates, SNEDDS (Self nano emulsifying drug delivery system) as this review paper depicts, as well as their rewards over conventional systems of drug delivery, as evidenced by improved biological activity depicted in their in vitro and in vivo anticancer assays.

11 October 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MKMonu Kumar Kashyap
Monu Kumar Kashyap
SMSHUBHADA V MANGRULKAR
SHUBHADA V MANGRULKAR
SKSapana Kushwaha
Sapana Kushwaha
AVAKASH VED
AKASH VED
MKMayur Bhimrao Kale
Mayur Bhimrao Kale
SKSpandana Rajendra Kopalli
Spandana Rajendra Kopalli
Cardiotoxicity is a well-known adverse effect of cancer-related therapy that has a significant influence on patient outcomes and quality of life. The use of antineoplastic drugs to treat colorectal cancers (CRCs) is associated with a number of undesirable side effects including cardiac complications. For both sexes, CRC ranks second and accounts for four out of every ten cancer deaths. According to the reports, almost 39% of patients with colorectal cancer who underwent first-line chemotherapy suffered cardiovascular impairment. Although 5-fluorouracil is still the backbone of chemotherapy regimen for colorectal, gastric, and breast cancers, cardiotoxicity caused by 5-fluorouracil might affect anywhere from 1.5% to 18% of patients. The precise mechanisms underlying cardiotoxicity associated with CRC treatment are complex and may involve the modulation of various signaling pathways crucial for maintaining cardiac health including TKI ErbB2 or NRG-1, VEGF, PDGF, BRAF/Ras/Raf/MEK/ERK, and the PI3/ERK/AMPK/mTOR pathway, resulting in oxidative stress, mitochondrial dysfunction, inflammation, and apoptosis, ultimately damaging cardiac tissue. Thus, the identification and management of cardiotoxicity associated with CRC drug therapy while minimizing the negative impact have become increasingly important. The purpose of this review is to catalog the potential cardiotoxicities caused by anticancer drugs and targeted therapy used to treat colorectal cancer as well as strategies focused on early diagnosing, prevention, and treatment of cardiotoxicity associated with anticancer drugs used in CRC therapy.

1 January 2014 in Toxicology International
Verified
Journal Article
Open access
AUAman B. Upaganlawar
Aman B. Upaganlawar
CUChandrashekhar Devidas Upasani
Chandrashekhar Devidas Upasani
RKReehan Khan
Reehan Khan
Present study was designed to evaluate the protective effects of ethanolic extract of Dioscorea alata L. (DA) on hematological and biochemical changes in aniline-induced spleen toxicity in rats. Wistar rats of either sex (200-250g) were used in the study and each group contains six rats. Splenic toxicity was induced in rats by administration of aniline hydrochloride (AH; 100 ppm) in drinking water for a period of 30 days. Treatment groups received DA (50 and 100 mg/kg/day, po) along with AH. At the end of treatment period, various serum and tissue parameters were evaluated. Rats administered with AH (100 ppm) in drinking water for 30 days showed a significant alteration in general parameters (organ weight, body weight, water intake, feed consumption, and fecal matter content), hematological parameters (red blood cell (RBC), white blood cell (WBC), and hemoglobin content), and biochemical parameters (total iron content, lipid peroxidation, reduced glutathione (GSH), and nitric oxide (NO) content) of spleen. Treatment with DA (50 and 100 mg/kg/day, po) for 30 days along with AH showed significant recovery in aniline-induced splenic toxicity. The present result showed that involvement of oxidative and nitrosative stress in aniline-induced splenic toxicity and DA protects the rats from the toxicity, which might be due to its antioxidant property and the presence of different phytochemicals.

15 June 2017 in American Journal of Biochemistry and Molecular Biology
Verified
Journal Article
Closed access
SDSanklecha Dhanshree
Sanklecha Dhanshree
AUAman B. Upaganlawar
Aman B. Upaganlawar
UCUpasani Chandrashe
Upasani Chandrashe